ストックスクリーナーアプリを入手
203.73
2.26%
-4.72
アフターアワーズ：
203.50
-0.23
-0.11%
Astrazeneca Plc (AZN) 最新ニュース
AstraZeneca PLC (NASDAQ:AZN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
AstraZeneca PLC $AZN Shares Bought by US Bancorp DE - MarketBeat
Harvest Portfolios Group Inc. Sells 20,219 Shares of AstraZeneca PLC $AZN - MarketBeat
AlphaCore Capital LLC Increases Stock Position in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Acquired by TD Asset Management Inc - MarketBeat
Erste Asset Management GmbH Sells 29,313 Shares of AstraZeneca PLC $AZN - MarketBeat
PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race - GlobeNewswire Inc.
AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange - FinancialContent
Thornburg Investment Management Inc. Sells 24,703 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca has 'sector leading replacement power' to cope with 2030 patent cliff - Proactive Investors
AstraZeneca (AZN) prices $2bn in new fixed-rate global bond tranches - Stock Titan
AstraZeneca prices $2 bln bond offering - marketscreener.com
Primecap Management Co. CA Sells 1,342,120 Shares of AstraZeneca PLC $AZN - MarketBeat
RWA Wealth Partners LLC Purchases 6,444 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLCAstraZeneca prices a $2bn bond offering - Research Tree
AstraZeneca Prices Three-tranche Global Bond Issue Worth $2 Billion - marketscreener.com
REGAstraZeneca PLCAstraZeneca prices a $2bn bond offering - TradingView
AstraZeneca’s Soriot Rewarded With $23m Pay But Still Lags Behind US Peers - Citeline News & Insights
AstraZeneca Advances Subcutaneous Durvalumab Study, Targeting More Convenient Cancer Care - TipRanks
Astrazeneca files 2025 annual report on Form 20-F with SEC - Investing.com
Astrazeneca files 2025 annual report on Form 20-F with SEC By Investing.com - Investing.com South Africa
Compound Planning Inc. Has $2.53 Million Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
Medicines: Oncology Portfolio and Pipeline - AstraZeneca
Assessing AstraZeneca (LSE:AZN) Valuation After Strong Recent Share Price Momentum - simplywall.st
[6-K] ASTRAZENECA PLC Current Report (Foreign Issuer) | AZN SEC FilingForm 6-K - Stock Titan
AstraZeneca Drug Price Challenge Falls Short In Hawaii - Law360
AstraZeneca boss Pascal Soriot nets £17.7m in pay and bonuses for 2025 - Yahoo Finance UK
AstraZeneca’s CLARITY-Gastric 02 Trial Targets New Front in Stomach Cancer - TipRanks
AstraZeneca Fails in Bid to Halt Hawaii 340B Drug Delivery Law - Bloomberg Law News
AstraZeneca publishes 2025 annual financial report and sets AGM for April - Investing.com South Africa
AstraZeneca announces board changes as Nazneen Rahman to retire in April By Investing.com - Investing.com South Africa
AstraZeneca announces board changes as Nazneen Rahman to retire in April - Investing.com
AstraZeneca (AZN) publishes 2025 Annual Report and sets 9 April 2026 AGM - Stock Titan
AstraZeneca (AZN) outlines non-executive board and committee changes - Stock Titan
AstraZeneca PLC Announces Directorate And Committee Changes, Effective April 9, 2026 - marketscreener.com
AstraZeneca boosts CEO Soriot's pay to about $24 million for 2025 - marketscreener.com
AstraZeneca announces retirement of non-executive director Nazneen Rahman - marketscreener.com
BRIEF-AstraZeneca Announces Retirement Of Non-Executive Director Nazneen Rahman - Devdiscourse
AstraZeneca : Directorate change - marketscreener.com
Transatlantique Private Wealth LLC Takes Position in AstraZeneca PLC $AZN - MarketBeat
Zevin Asset Management LLC Sells 7,994 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Sold by Vestmark Advisory Solutions Inc. - MarketBeat
Legacy Financial Advisors Inc. Invests $1.06 Million in AstraZeneca PLC $AZN - MarketBeat
FDA Gives Green Light to AstraZeneca's All-Oral Calquence-Venetoclax Combo for CLL - StockInvest.us
Marks Group Wealth Management Inc Buys 5,896 Shares of AstraZeneca PLC $AZN - MarketBeat
Westerkirk Capital Inc. Invests $906,000 in AstraZeneca PLC $AZN - MarketBeat
Fact Check: No, AstraZeneca Vaccine Does Not Mean 'Path to Death' - Tempo.co English
AstraZeneca PLC (LON:AZN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026? - The Globe and Mail
AstraZeneca (AZN) Gains FDA Orphan Designation for Follicular Ly - GuruFocus
AstraZeneca Secures US Approval For Fixed-duration Calquence Regimen In CLL - DirectorsTalk Interviews
AstraZeneca receives US approval for fixed-duration Calquence and venetoclax combination in CLL By Investing.com - Investing.com South Africa
Woodley Farra Manion Portfolio Management Inc. Lowers Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Purchased by Synovus Financial Corp - MarketBeat
Wealthcare Advisory Partners LLC Buys 19,612 Shares of AstraZeneca PLC $AZN - MarketBeat
FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer - Benzinga
AstraZeneca receives US approval for fixed-duration Calquence and venetoclax combination in CLL - Investing.com Nigeria
AstraZeneca Says US FDA Approves Calquence Combo for Certain Blood Cancer Patients - marketscreener.com
AstraZeneca's (AZN) Calquence Gains FDA Approval for New Leukemi - GuruFocus
AstraZeneca's (AZN) Calquence Gains FDA Approval for Leukemia Tr - GuruFocus
China Universal Asset Management Co. Ltd. Has $10.25 Million Holdings in AstraZeneca PLC $AZN - MarketBeat
1.04%
0.94%
大文字化:
|
ボリューム (24 時間):